$0.84
▼ -0.4% Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC
Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
Overview
52-week range
$0.73
$1.51
14% of range
Avg surprise (last 3)
+9.3%
Avg reaction (last 2)
-0.9%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.08 | — | — | — | — | financials |
| Thu May 14, 2026 | Mar/2026 | $-0.08 | $-0.05 | -60.0% | -33.3% | 0.0% | earnings |
| Fri Aug 8, 2025 | Jun/2025 | $-0.05 | $-0.11 | +54.5% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.06 | $-0.09 | +33.3% | — | -1.9% | earnings |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-9M | $-9M | — | $-5M | $-5M |
| Net income | $-9M | $-9M | — | $-5M | $-5M |
| EPS (diluted) | $-0.08 | $-0.08 | — | $-0.06 | $-0.06 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $4M | $5M | $5M | — | — |
| Inventory | — | — | — | — | — |
| Total current assets | $7M | $7M | $7M | — | — |
| Total assets | $8M | $8M | $8M | — | — |
| Long-term debt | — | — | — | — | — |
| Total liabilities | $14M | $13M | $11M | — | — |
| Total equity | $-6M | $-5M | $-4M | $4M | $4M |
Implied volatility — last 90 days
No IV snapshots yet for ONCY.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.